EP2173326A2 - Dermatologische zusammensetzungen mit calcitriol-lipidvesikeln, verfahren zu ihrer herstellung und verwendung dafür - Google Patents

Dermatologische zusammensetzungen mit calcitriol-lipidvesikeln, verfahren zu ihrer herstellung und verwendung dafür

Info

Publication number
EP2173326A2
EP2173326A2 EP08806120A EP08806120A EP2173326A2 EP 2173326 A2 EP2173326 A2 EP 2173326A2 EP 08806120 A EP08806120 A EP 08806120A EP 08806120 A EP08806120 A EP 08806120A EP 2173326 A2 EP2173326 A2 EP 2173326A2
Authority
EP
European Patent Office
Prior art keywords
composition according
composition
calcitriol
phase
oily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08806120A
Other languages
English (en)
French (fr)
Inventor
Lara Baudonnet
Claire Mallard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma SA
Original Assignee
Galderma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma SA filed Critical Galderma SA
Publication of EP2173326A2 publication Critical patent/EP2173326A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Definitions

  • Dermatological composition comprising calcitriol lipid vesicles, process for its preparation and its use
  • the present invention relates to a pharmaceutical composition, especially dermatological, based on a compound of the family of vitamin D derivatives, and more particularly calcitriol, said vitamin D derivative being present in oily vesicles dispersed in a aqueous phase. It also relates to its preparation process and its use in the preparation of a medicament for the treatment of dermatological conditions, in particular psoriasis.
  • Vitamin D derivatives especially calcitriol, are used to regulate calcium levels in the body.
  • the use of calcitriol in the treatment of dermatological diseases has in particular been described in US Pat. No. 4,610,978 for the treatment of psoriasis.
  • compositions commonly encountered in the prior art contain a high percentage of propenetrating glycol in order to promote the penetration of the active ingredient but are sticky and can cause problems of intolerance (" and patient compliance "Piacquadio & Garlic, Journal of the American Academy of Dermatology, August 1998).
  • the problem that the present invention proposes to solve here is therefore to design a physically and chemically stable composition containing at least one vitamin D derivative, preferably calcitriol, for the treatment of psoriasis, the composition according to the invention being also present an ease of use and acceptable cosmetics for application to all areas of the body that may be affected by the pathology.
  • the object of the present invention is to provide a hydrophilic formulation based on vitamin D derivative, preferably calcitriol, as an alternative to Silkis® ointment forms.
  • This formulation would bring more comfort to the patient and ensure better adherence to treatment.
  • vitamin D derivatives and in particular calcitriol are unstable in aqueous media, and sensitive to acidic pH.
  • the objective of the present invention is therefore to provide an aqueous composition which makes it possible to overcome a degradation of the vitamin D derivative, preferably calcitriol, while retaining good cosmetic properties. To this end, it seems interesting to work on the structure of the interface between the solubilization medium of the vitamin D derivative, preferably calcitriol, and the aqueous phase.
  • CN 1491551 discloses nanocapsule formulations with the active ingredient ivermectin suspended in water produced via polymeric emulsions, i.e. a solvent-free process employing in-situ polymerization of monomer.
  • patent FR 2 805 761 discloses lipid nanocapsules containing phosphatidylcholines in combination with a hydrophilic co-surfactant derived from polyethylene glycol, Solutol HS 15.
  • a hydrophilic co-surfactant derived from polyethylene glycol, Solutol HS 15.
  • co-surfactant is necessary for the production of nanocapsules.
  • the method for preparing such nanocapsules is by phase inversion (TIP process), which generates the use of temperature cycles in the process.
  • the active ingredients are solubilized in an oil composed of medium chain triglycerides of caprylic and capric acids, marketed under the name Labrafac WL1349 by GATTEFOSSE.
  • compositions comprising at least one vitamin D derivative, preferably calcitriol, in solubilized form in a dispersed oily phase make it possible to stabilize this active ingredient and are easy to prepare.
  • Such compositions comprise at least one vitamin D derivative, preferably calcitriol, in solubilized form in a hydrophilic environment, do not require the use of polymer or organic solvent, and guarantee the stability of the active ingredient. They can also promote skin penetration of the asset, which is useful in the treatment of dermatological conditions, including psoriasis.
  • compositions in particular a pharmaceutical composition, comprising at least one vitamin D derivative, preferably calcitriol, said composition comprising, within a pharmaceutically acceptable vehicle, lipid vesicles consisting of: less a vitamin D derivative;
  • lipid vesicles being dispersed in a continuous hydrophilic phase.
  • composition according to the invention comprises from 0.00001 to 0.1% of at least one vitamin D derivative by weight relative to the total weight of the composition, preferably from 0.0001 to 0.001%.
  • composition according to the invention contains 0.0001% and 0.001% of calcitriol.
  • lipid vesicle composition is meant a colloidal lipid system comprising lipid vesicles with solid or semi-solid interface dispersed in a continuous hydrophilic phase, said vesicles containing an oily internal phase in which the vitamin D derivative, from calcitriol is preferably solubilized, and a lamellar coating obtained from at least one non-polymeric surfactant forming the semi-solid or solid interface between the oily internal phase and the continuous hydrophilic phase.
  • derivatives of vitamin D is meant calcitriol, calcipotriol, ⁇ 4- [6-Ethyl-4 '- (1-ethyl-1-hydroxy-propyl) -2'-propyl-biphenyl-3-yloxymethyl] 2-hydroxymethyl-phenyl ⁇ -methanol.
  • the derivative used is calcitriol.
  • composition according to the invention is meant the composition of lipid vesicles, incorporated in a pharmaceutically acceptable vehicle, such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
  • a pharmaceutically acceptable vehicle such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
  • pharmaceutically acceptable vehicle is meant an excipient or a mixture of excipients component, with the nanoemulsion, the composition according to the invention.
  • the present invention relates to compositions comprising vesicles made without organic solvent.
  • the composition comprises vesicles and not nanospheres.
  • vesicles means particles consisting of a liquid or semi-liquid core (internal phase) at ambient temperature, encapsulated by a solid non-polymeric coating (shell or layer) at room temperature, as opposed to nanospheres which are matrix particles. , ie whose whole mass is solid.
  • the nanospheres contain a pharmaceutically acceptable active ingredient, it is finely dispersed in the solid matrix.
  • lipid vesicle is understood to mean a vesicle whose heart is composed of one or more liquid or semi-liquid fatty substances at ambient temperature, and whose coating is of a lipophilic and non-polymeric nature. Indeed, the lipid vesicles according to the invention do not require any polymer and therefore no in situ polymerization. In the present application, we speak indifferently of "lipid vesicles” or “vesicles”.
  • ambient temperature is meant a temperature of between 15 and 25 ° C.
  • the lipid vesicles according to the present invention have an average size of less than 200 nm, preferably less than 150 nm.
  • lipid vesicles are present in the composition according to the invention in an amount of between 10 and 30% by weight relative to the total weight of the composition, preferably between 10 and 20%.
  • the vesicles each consist of a liquid or semi-liquid core at ambient temperature, coated with a lamellar coating obtained from at least one surfactant.
  • the coating (envelope or layer) of surfactant encapsulating the vesicles is preferably composed of a solid material at room temperature. It is not polymeric in nature. Preferably, it has a liquid crystal structure.
  • This coating consists of one or more lipophilic surfactants; advantageously, such lipophilic surfactant (s) are chosen from anionic amphiphilic lipids. More preferably, the surfactant (s) are chosen from the family of phospholipids, preferably from the family of lecithins, and preferably the lipophilic surfactant is a hydrogenated lecithin, advantageously including the percentage of saturated phosphatidylcholine (or hydrogenated) is high. High percentage means a quantity of 70 to 99% of saturated phosphatidylcholine (or hydrogenated) relative to the total weight of lecithin. Phosphatidylcholines show good compatibility with the skin with a very low irritating potential.
  • the lecithin used in the present invention being solid at room temperature, this promotes the formation of a semi-solid interface in the composition.
  • lecithins As usable lecithins, mention may be made in particular of natural or synthetic soy or egg lecithins having a content of hydrogenated phosphatidylcholine greater than 70%, for example LIPOID of grade S75-3, S100-3 or SPC-3. Epikuron grade 200 SH or 10OH, or Phospholipon grade 8OH, 9OH or 10OH.
  • the coating of lipophilic surfactant enveloping the liquid or semi-liquid core as defined above is present in an amount of between 0.1 and 10% by weight, preferably between 1 and 5% by weight relative to the total weight of the composition. .
  • the coating of lipophilic surfactant, in particular lecithin, according to the invention alone allows the encapsulation of the vitamin D derivative, in particular calcitriol, which avoids the contact of this active agent with the hydrophilic phase, and thus provides it with the chemical stability.
  • the composition, and in particular the coating is substantially free of co-surfactant distinct from the anionic amphiphilic lipids, thus substantially free of co-surfactant distinct from the phospholipids, and in particular substantially free of hydrophilic co-surfactant.
  • the composition does not contain any co-surfactant other than ionic amphiphilic lipids.
  • the vitamin D derivative especially calcitriol, is thus solubilized in the heart of the vesicles.
  • Said core, or oily internal phase comprises at least one liquid or semi-liquid fatty substance at ambient temperature.
  • composition of the internal phase is therefore essential for the stability of the active ingredient.
  • oily internal phase must of course be compatible with the asset to be solubilized.
  • This oily internal phase comprises at least one oily solvent, chosen from tocopherol esters, and triglycerides and oils containing them.
  • the oily solvent is selected from vitamin E acetate and caprylic / capric acid triglycerides, such as Miglyol 812.
  • the internal phase may also comprise one or more non-solubilizing liquid or semi-liquid at room temperature fatty substances of the active ingredient, such as: 2-alkyl alkanols and their esters, such as: butyloctanol, hexyldecanol, octyldecanol, isostearyl alcohol, octyldodecanol, decyltetradecanol, undecylpentadecanol, dodecylhexadecanol, tetradecyloctadecanol, hexyldecyloctadecanol, tetradecylicosanol, cetylarachidol and the mixture of iso-cetyl alcohol, iso-stearyl alcohol, iso-arachidyl alcohol.
  • 2-alkyl alkanols and their esters such as: butyloctanol, hexyldecanol, o
  • esters of said alcohols mention may be made of: octyldodecyl octanoate; hexyldecyl caprylate; hexyldecyl laurate; hexyldecyl palmitate; hexyldecyl stearate; and octyldodecyl meadowfoamate, which is an ester of octyldodecanol and fatty acids derived from meadowfoam seed oil Alba;
  • esters of fatty acids or of fatty alcohols such as isopropyl palmitate, isostearyl neopentanoate and octyl palmitate;
  • N-acetylated amino acid esters and fatty alcohol such as N-lauroyl isopropyl sarcosinate
  • non-solubilizing fatty substance of the active is meant a compound for which the vitamin D derivative has a solubility of less than or equal to 1%.
  • Such a fatty substance is present in an amount of between 90 and 99.99% by weight relative to the total weight of the internal phase; and in an amount of between 1 and 25% by weight relative to the total weight of the composition, preferably between 5 and 15%.
  • the continuous hydrophilic phase comprises water.
  • This water may be demineralized water, floral water such as blueberry water, or natural thermal or mineral water, for example chosen from Vittel water, Vichy basin water Uriage, the water of the Roche Posay, the water of the Bourboule, the water of Enghien-les-Bains, the water of Saint Gervais-les-Bains, the water of Néris-les-Bains, the water of Allevard-les-Bains, the water of Digne, the water of Maiz restaurants, the water of Neyrac-les-Bains, the water of Lons-le-Saunier, the Good Waters, the water Rochefort, the water of Saint Christau, the water of the Fumades and the water of Tercis-les-bains, the water of Avène or the water of Aix les Bains.
  • the water may be present at a content of between 70 and 90% by weight relative to the total weight of the composition, preferably between 80 and 90% by weight.
  • the hydrophilic phase may also comprise other hydrophilic compounds such as preservatives or humectants.
  • preservatives such as parabens or phenoxyethanol.
  • humectants such as glycerine.
  • the hydrophilic phase may also comprise active principles not sensitive to the presence of water, these active ingredients being useful in the treatment of dermatological pathologies.
  • the corticosteroid is selected from the group consisting of betamethasone, clobetasol, clobetasone, deoximethasone, diflucortolon, diflorasone, fluocinonide, flumethasone, fluocinolon, fluticasone, fluprednidene, halcinonide, hydrocortisone, momethasone, triamcinolon and their pharmaceutically acceptable esters and acetonides and mixtures thereof.
  • esters or acetonides mention may be made of those selected from the group consisting of 17-valerate, 17-propionate, 17,21-dipropionate, acetonide, acetonide-21 -N benzoyl-2-methyl- ⁇ -alaninate, acetonide-21- (3,3-dimethylbutyrate) and 17-butyrate.
  • the hydrophilic phase may comprise clobetasol 17-propionate (or "clobetasol propionate").
  • the amount of corticosteroid in solubilized form in the hydrophilic phase of the composition of the invention is from 0.00005 to 3% by weight relative to the total weight of the composition, preferably from 0.0001 to 1% by weight. and more particularly from 0.001 to 0.1% by weight.
  • the corticosteroids present in the composition as described above may be present within the oily vesicles according to the present invention. In this case, they end up in the oily inner phase which includes the solubilized vitamin D derivative.
  • the gelling agent may also be chosen from natural gums such as tragacanth gum, guar gum, acacia gum, gum arabic, starch and its derivatives, copolymers of polyacrylic acid and methylmethacrylate, carboxyvinyl polymers, polyvinyl pyrrolidones and their derivatives, polyvinyl alcohols, sodium alginate, pectin, dextrin, chitosan, alone or as a mixture.
  • natural gums such as tragacanth gum, guar gum, acacia gum, gum arabic, starch and its derivatives, copolymers of polyacrylic acid and methylmethacrylate, carboxyvinyl polymers, polyvinyl pyrrolidones and their derivatives, polyvinyl alcohols, sodium alginate, pectin, dextrin, chitosan, alone or as a mixture.
  • the gelling agent is used in particular at a concentration of between 0.1 and 10% by weight, preferably between 0.1 and 2% by weight.
  • the lipid vesicle composition as described above is incorporated in a pharmaceutically acceptable vehicle, such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
  • a pharmaceutically acceptable vehicle such as a gel, a gel-cream or an emulsion such as a cream or a lotion.
  • pharmaceutically acceptable vehicle is meant an excipient or a mixture of component excipients, the composition according to the invention.
  • composition in particular a pharmaceutical composition, said composition comprising the nanoemulsion containing the lipid nano-vesicles defined above in the text of the present invention in a pharmaceutically acceptable vehicle, such as a gel, a gel, cream or emulsion as a cream or lotion.
  • a pharmaceutically acceptable vehicle such as a gel, a gel, cream or emulsion as a cream or lotion.
  • the nanoemulsion is dispersed in a hydrophilic phase which comprises at least one gelling agent.
  • This gelling agent is preferably a cellulose derivative chosen from semi-synthetic cellulosic gelling agents, such as methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, carboxymethylcellulose, hydroxymethylcellulose, and hydroxypropylcellulose, taken alone or in mixture. Hydroxypropylmethylcellulose or hydroxyethylcellulose is preferably used.
  • the gelling agent may also be chosen from natural gums such as tragacanth gum, guar gum, acacia gum, gum arabic, starch and its derivatives, copolymers of polyacrylic acid and methylmethacrylate, carboxyvinyl polymers, polyvinyl pyrrolidones and their derivatives, polyvinyl alcohols, biopolymers such as sodium alginate, pectin, dextrin, chitosan, sodium hyaluronate and their derivatives alone or as a mixture, the agent gelling agent may also be chosen from Sepigel 305 compound consisting of a polyacrylamide / isoparaffin C13-C14 / laureth-7 mixture, or Simulgel 600PHA, namely sodium acryloyld
  • the gelling agent is used in particular at a concentration of between 0.1 and 10% by weight, preferably between 0.1 and 2% by weight relative to the total weight of the composition.
  • the pharmaceutically acceptable vehicle is a gel-cream
  • the nanoemulsion is dispersed in a vehicle composed of a hydrophilic phase and a fatty phase,
  • the nanoemulsion is dispersed in a vehicle composed of a hydrophilic phase, a fatty phase, and at least one surfactant or emulsifier.
  • the composition according to the invention therefore comprises a fatty phase.
  • This fatty phase may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, and mixtures thereof.
  • mineral oil there may be mentioned, for example, paraffin oils of different viscosities such as Primol 352®, Marcol 82®, Marcol 152® sold by the company Esso.
  • sweet almond oil there may be mentioned sweet almond oil, palm oil, soybean oil, sesame oil, sunflower oil.
  • an ester such as cetearyl isononanoate, such as the product sold under the name Cetiol SN PH® by Cognis France, and isopropyl palmitate, as the product sold under the name Crodamol IPP® by the company Croda company, diisopropyl adipate sold under the name Crodamol DA by the company Croda, caprylic / capric triglyceride such as Miglyol 812® sold by the company HuIs / Univar.
  • volatile or non-volatile silicone oil mention may be made of dimethicones, such as the products sold under the name Q7-9120® silicone fluid with a viscosity of 20 to 12500 is, or the product sold under the name ST-Cyclomethicone-5 NF® by the Dow corning company.
  • solid fatty substances such as natural or synthetic waxes, fatty acids such as stearic acid, fatty alcohols such as Speziol C18 pharma sold by Cognis, and tribehenate type texturing agents, such as Compritol 888 sold by Gattefossé or hydrogenated castor oils such as Cutina HR sold by Cognis. In this case, those skilled in the art will adapt the heating temperature of the preparation depending on the presence or absence of these solids.
  • the emulsion when the vehicle of the composition according to the invention is an emulsion, the emulsion is in the form of an oil-in-water (O / W) emulsion.
  • the emulsion therefore comprises at least one emulsifier.
  • the preferred concentrations of emulsifiers are between 0.001 and 20% by weight relative to the total weight of the composition. More preferably the concentration is between 1 and 15% and preferably between 3 and 1 1% by weight relative to the total weight of the composition.
  • the emulsifying power of emulsifiers is closely related to the polarity of the molecule. This polarity is defined by the HLB (Hydrophile / Lipophilic Balance).
  • High HLB indicates that the hydrophilic moiety is predominant, and conversely, low HLB indicates that the lipophilic moiety is predominant.
  • HLB values greater than about 10 correspond to hydrophilic surfactants.
  • Emulsifiers can be classified, according to their structure, under the generic terms "ionic” (anionic, cationic, amphoteric) or "nonionic".
  • Nonionic emulsifiers are emulsifiers that do not dissociate into ions in water and are therefore insensitive to pH changes.
  • Nonionic emulsifiers are particularly well suited for the preparation of oil-in-water type emulsions, object of the present invention.
  • the emulsifying system, component of the emulsion of the invention comprises at least one non-ionic emulsifier with predominantly hydrophilic fraction, that is to say having a high HLB greater than about 10.
  • said nonionic emulsifiers having low HLB have an HLB of less than 10.
  • the nonionic emulsifiers can be used alone or in a mixture of two or more of them to form the emulsifying system comprising the emulsion of the invention.
  • one or more pairs of "nonionic emulsifier of high HLB” / "nonionic emulsifier of low HLB” will be used as an emulsifying system, it may in particular be a nonionic emulsifying system comprising at least a nonionic emulsifier having an HLB greater than about 10 and at least one nonionic surfactant having an HLB of less than about 10.
  • the ratio of each of the two emulsifiers forming the abovementioned pair is most often determined by the calculation of the required HLB of the fat phase used.
  • hydrophilic emulsifiers of the type, Glycery! Stearate & PEG-100 Stearate sold under the name Arlacel 165FL® by Uniqema; PEG 6 stearate and PEG 32 stearate sold under the name TEFOSE 1500® by Gattefossé, PEG 20 methyl glucose sesquistearate sold under the name Glucamate SSE 20® by Amerchol, Poiyoxyethyiene (21) Stéasy!
  • the emulsifiers are amphiphilic compounds which have a hydrophobic part having an affinity for the oil and a hydrophilic part having an affinity for water thus creating a link between the two phases. Ionic or nonionic emulsifiers thus stabilize O / W emulsions by adsorbing at the interface and forming lamellar layers of liquid crystals.
  • the oil-in-water emulsion according to the invention also comprises a hydrophilic phase or an aqueous phase.
  • hydrophilic phase which constitutes the pharmaceutically acceptable vehicle, alone or within an emulsion, is meant any hydrophilic phase as defined previously in the present invention.
  • composition according to the invention may also contain, within the nanoemulsion or the pharmaceutically acceptable vehicle, additives or combinations of additives, such as: preserving agents;
  • UV-A and UV-B filters are UV-A and UV-B filters
  • glycols for example propylene glycol, glycol ethers, N-methyl-2-pyrrolidone or else dimethylsulfoxide.
  • additives may be present in the composition from 0 to 20% by weight relative to the total weight of the composition.
  • the usable pharmaceutical composition consisting of the composition of lipid vesicles in a pharmaceutically acceptable vehicle according to the invention is intended for the treatment of the skin and may be administered topically, parenterally or orally. Preferably, the composition is administered topically. Topically, we mean an application on the skin or the mucous membranes.
  • the pharmaceutical composition may be in liquid or pasty form, and more particularly in the form of capsules, dragees, or syrups.
  • composition may be in the form of suspensions for infusion or for injection.
  • the composition may be in liquid or pasty form, and more particularly in the form of creams, milks, ointments, soaked swabs, syndets, wipes, gels, sprays, foams, lotions, sticks, shampoos, or washing bases.
  • composition according to the invention comprises, in a pharmaceutically acceptable vehicle, by weight relative to the total weight of the composition: a) 0.1 to 5% of surfactant chosen from anionic amphiphilic lipids, preferably lecithin; b) 1 to 50% of liquid or semi-liquid fat at room temperature, preferably tocopherol esters such as vitamin E acetate or triglycerides of caprylic / capric acids; preferably from 10 to 25% c) between 0.00001 and 0.1% of at least one derivative of vitamin D, preferably calcitriol; d) 0 to 2% gelling agent, preferably a cellulose derivative.
  • surfactant chosen from anionic amphiphilic lipids, preferably lecithin
  • tocopherol esters such as vitamin E acetate or triglycerides of caprylic / capric acids
  • d) 0 to 2% gelling agent preferably a cellulose derivative.
  • the invention also relates to a process for preparing compositions comprising at least one derivative of vitamin D, preferably calcitriol.
  • This process uses a High Pressure Homogenizer (HHP).
  • HHP High Pressure Homogenizer
  • the method according to the invention does not use a Phase Inversion Temperature (TIP) (used in particular in patents FR 2 805 761 and FR 2 840 531), and therefore does not require a cycle (s). rise and fall in temperature.
  • TIP Phase Inversion Temperature
  • the process according to the invention is carried out in cold HHP; HHP therefore does not require successive heating and cooling, and is not thermoregulated.
  • the method implemented in the present invention comprises the following steps:
  • calcitriol is solubilized in the fatty substance, for example vitamin E acetate or triglycerides of caprylic / capric acids.
  • the lipophilic surfactant in particular lecithin, for example, Phospholipon 9OH or Lipoid S75-3 is dispersed in the oily phase.
  • the two phases are preferably separately heated to a temperature preferably greater than 50 ° C.
  • the lipophilic phase is heated to about 60 ° C to facilitate dispersion of the surfactant (step (Ni)).
  • the lipophilic phase is allowed to cool before the incorporation of the vitamin D derivative solution (step (i)), in order to avoid any degradation thereof related to the temperature of implementation of the vesicles.
  • step (iv) Mixing of the oily and hydrophilic phases obtained at the end of step (iii). Once the two phases in temperature, about 50 ° C, they are mixed with stirring. Once this pre-homogenization has been carried out, the emulsion is introduced into the High Pressure Homogenizer (HHP).
  • HHP High Pressure Homogenizer
  • the composition is not heated, the HHP system is not controlled temperature.
  • the step of gelation of the composition takes place at the end of manufacture after the various passages in the HHP, during the cooling of the composition.
  • the gelling agent is then added with sufficient stirring to a homogeneous dispersion, during the cooling of the composition. Stirring is maintained for the time necessary to complete the gelation step of the system.
  • the gel-cream or the emulsion is carried out beforehand. Then the lipid vesicle composition is incorporated into the finalized vehicle.
  • the process may be adapted by those skilled in the art depending on the different ingredients used to maintain the stability of the lipid vesicles within the final composition.
  • composition according to the invention can be used as a medicament.
  • the subject of the invention is also the use of the composition according to the invention for the preparation of a medicament intended to treat dermatological affections, in particular human affections.
  • the use of the composition according to the invention is more particularly intended for the treatment of psoriasis.
  • the composition according to the invention is indeed suitable for use in the treatment of dermatological conditions, especially human, and preferably for the treatment of psoriasis.
  • compositions comprising a vitamin D derivative, and especially calcitriol, will now be given.
  • Example 1 Preformulation Study of Calcitriol Preliminary preformulation studies were conducted to guide the choice of lipid core (oily internal phase) of our lipid vesicles.
  • the graphs below present the results of tests of stability and solubility of calcitriol in two excipients: These studies of solubility and stability of calcitriol aim at finding the oil which will allow a good solubility of calcitriol for the proposals of phase used in this concept and good stability of calcitriol in this excipient.
  • Calcitriol is stable for 1 month at 800 ppm at all three temperatures (4 ° C, Tamb and 40 9 C) in Miglyol 812 (caprylic / capric triglyceride: MTC) and tocopherol acetate.
  • the method implemented in this invention utilizes a High Pressure Homogenizer (HHP).
  • HHP High Pressure Homogenizer
  • the hydrogenated phosphatidylcholine used is dispersed in the oily phase as a function of the phosphatidylcholine content.
  • the oily phase is heated to about 75 ° C to ensure the dispersion of phosphatidylcholine in this phase.
  • the temperature of this phase must be about 50 ° C, in order to avoid a degradation of the calcitriol linked to the temperature of implementation of lipid vesicles.
  • the hydrophilic phase is heated to about 50 ° C.
  • the two phases in temperature are mixed with stirring (turrax homogenization for 2 minutes at 8000 rpm). Once this pre-homogenization has been carried out, the emulsion is introduced into the HHP.
  • the use of a high pressure homogenizer requires setting the number of passages in the homogenization chamber and the homogenization pressure.
  • the Homogenization process is then applied: minimum 500 bar up to 1000 bar of homogenization pressure in the homogenization chamber, between 5 and 10 passages in the homogenization chamber.
  • the nanoemulsion is not heated, the HHP system is not controlled temperature.
  • the step of gelation of the composition occurs at the end of manufacture after the various passages in the HHP, during the cooling of the composition .
  • the gelling agent is then added with sufficient stirring to a homogeneous dispersion, during the cooling of the composition, or the gelling agent is hydrated in a part of water of our system and then diluted at the end of manufacture.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08806120A 2007-06-29 2008-06-27 Dermatologische zusammensetzungen mit calcitriol-lipidvesikeln, verfahren zu ihrer herstellung und verwendung dafür Withdrawn EP2173326A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0756165A FR2917976B1 (fr) 2007-06-29 2007-06-29 Composition dermatologique comprenant des vehicules lipidiques de calcitriol, son procede de preparation et son utilisation
PCT/FR2008/051193 WO2009007622A2 (fr) 2007-06-29 2008-06-27 Composition dermatologique comprenant des vésicules lipidiques de calcitriol, son procédé de préparation et son utilisation

Publications (1)

Publication Number Publication Date
EP2173326A2 true EP2173326A2 (de) 2010-04-14

Family

ID=38957738

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08806120A Withdrawn EP2173326A2 (de) 2007-06-29 2008-06-27 Dermatologische zusammensetzungen mit calcitriol-lipidvesikeln, verfahren zu ihrer herstellung und verwendung dafür

Country Status (5)

Country Link
US (1) US20100221350A1 (de)
EP (1) EP2173326A2 (de)
CA (1) CA2691398A1 (de)
FR (1) FR2917976B1 (de)
WO (1) WO2009007622A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2942050T3 (da) * 2014-05-06 2022-11-21 S I I T S R L Servizio Int Imballaggi Termosaldanti Spraybar, olieholdig sammensætning baseret på fedtopløselige vitaminer fra gruppe d og anvendelse deraf
FR3041541B1 (fr) * 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
CN112630257B (zh) * 2020-12-28 2024-03-22 宁波铭瑞中兴电子科技有限公司 一种玻璃水水箱监控方法、系统、智能终端以及存储介质

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
US4911928A (en) * 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
FR2735658B1 (fr) * 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
FR2709666B1 (fr) * 1993-09-07 1995-10-13 Oreal Composition cosmétique ou dermatologique constituée d'une émulsion huile dans eau à base de globules huileux pourvus d'un enrobage cristal liquide lamellaire.
FI100692B (fi) * 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
EP0892638B1 (de) * 1996-04-04 2002-11-13 Cilag AG Topische vitamin d zusammensetzung auf liposomenbasis
GB9906009D0 (en) * 1999-03-16 1999-05-12 Nycomed Pharma As Product
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
ES2259034T3 (es) * 2000-06-06 2006-09-16 Basf Aktiengesellschaft Uso de un enantiomero del acido lipoico en cosmeticos y dermatologicos.
FR2871698B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009007622A2 *

Also Published As

Publication number Publication date
FR2917976A1 (fr) 2009-01-02
WO2009007622A2 (fr) 2009-01-15
CA2691398A1 (fr) 2009-01-15
FR2917976B1 (fr) 2010-05-28
US20100221350A1 (en) 2010-09-02
WO2009007622A3 (fr) 2009-05-22

Similar Documents

Publication Publication Date Title
EP2854793B1 (de) Lipidnanokapseln mit einem retinoid, nanodispersion und zusammensetzung damit, verfahren zur herstellung davon und verwendung davon in der dermatologie
EP2224908B1 (de) Zusammensetzungen mit mindestens einem naphthoesäurederivat, benzoylperoxid und mindestens einem filmbildenden mittel, verfahren zu ihrer herstellung und anwendungen davon
DE69331335T2 (de) Topisches und transdermales abgabesystem unter verwendung von submikron-ölkügelchen
EP2125117B1 (de) Emulsion mit mindestens einem retinoid und benzoylperoxid
EP1915133A1 (de) Öl-in-wasser-emulsion für topische anwendung in der dermatologie
EP2388009B1 (de) Dermatologische Zusammensetzungen mit Avermectin-Nanokapseln, Verfahren zu ihrer Herstellung und ihre Verwendung
EP3076944A1 (de) Lipidmikrokapseln, vorzugsweise mit einem lipophilen wirkstoff und zusammensetzung damit, verfahren zur herstellung und verwendung in der dermatologie und kosmetik
EP2240152B1 (de) Zusammensetzung mit einem retinoid und dispergiertem benzoylperoxid
EP1758588B1 (de) Pharmazeutische zusammensetzung mit einer salbe und zwei aufgelösten wirkstoffen
Tungadi et al. Transdermal delivery of snakehead fish (Ophiocephalus striatus) nanoemulgel containing hydrophobic powder for burn wound
EP2173326A2 (de) Dermatologische zusammensetzungen mit calcitriol-lipidvesikeln, verfahren zu ihrer herstellung und verwendung dafür
EP2872116B1 (de) Dermatologische zusammensetzung mit oleosomen und retinoiden, verfahren zur herstellung davon und verwendung davon
EP2029133B1 (de) Zusammensetzungen mit mindestens einem naphthoesäurederivat und mindestens einem filmbildenden mittel, herstellungsverfahren und verwendung
EP3302421B1 (de) Zusammensetzungen mit mindestens einem dispergierten wirkstoff und lipid-mikrokapseln
FR2924943A1 (fr) Composition dermatologique comprenant des nanocapsules polymeriques de calcitriol, son procede de preparation et son utilisation
Demirtürk Preprint not peer reviewed

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100129

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

17Q First examination report despatched

Effective date: 20120223

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130208